LSTA-12 Market Size, Forecast, and Emerging Insight - 2032

This “LSTA-12 Market Size, Forecast, and Emerging Insight − 2032” report provides comprehensive insights about LSTA-12 for Peripheral Artery Disease (PAD) in Japan. A detailed picture of the LSTA-12 for PAD in Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the LSTA-12 for PAD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the LSTA-12 market forecast analysis for PAD in Japan, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PAD.

Drug Summary

LSTA-12 (also known as Honedra and CLBS12 in Japan) is an experimental regenerative medicine to prevent the serious adverse consequences of CLI and Buerger's disease by improving blood flow in the affected limb. It is CD34+ cell therapy intended to administer by Intramuscular route, 20 injections in the target limb in a single treatment.

The CD34+ cell was discovered due to the deliberate search for a stem cell capable of stimulating blood vessels' development and/or repair. All tissues in the human body maintain their function by replacing cells over time. By administering CD34+ cells, the company promotes the development and formation of new microvasculature, thereby increasing blood flow to the impacted area. No other native cell discovered to date has demonstrated this same capability.

The initial clinical responses are consistent with a positive therapeutic effect and safety profile and with previously published clinical trials of CD34+ cell therapy in Japan and elsewhere.

Caladrius' proprietary CD34+ cell therapy technology has led to the development of therapeutic product candidates designed to address diseases and conditions caused by ischemia. Ischemia occurs when the supply of oxygenated blood to healthy tissue is restricted. Caladrius believes that several conditions caused by underlying ischemic injury can be improved through its CD34+ cell technology, including but not limited to coronary microvascular dysfunction (CMD), critical limb ischemia (CLI), diabetic kidney disease (DKD), and no-option refractory disabling angina (NORDA).

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the LSTA-12 description, mechanism of action, dosage and administration, research and development activities in Peripheral Artery Disease (PAD).
• Elaborated details on LSTA-12 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the LSTA-12 research and development activities in PAD across Japan.
• The report also covers the patents information with expiry timeline around LSTA-12.
• The report contains forecasted sales of LSTA-12 for PAD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for PAD.
• The report also features the SWOT analysis with analyst views for LSTA-12 in PAD.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LSTA-12 Analytical Perspective

In-depth LSTA-12 Market Assessment

This report provides a detailed market assessment of LSTA-12 for Peripheral Artery Disease (PAD) in Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

LSTA-12 Clinical Assessment

The report provides the clinical trials information of LSTA-12 for PAD covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Peripheral Artery Disease (PAD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence LSTA-12 dominance.
• Other emerging products for PAD are expected to give tough market competition to LSTA-12 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of LSTA-12 in PAD.
• This in-depth analysis of the forecasted sales data of LSTA-12 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the LSTA-12 in PAD.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of LSTA-12?
• What is the clinical trial status of the study related to LSTA-12 in Peripheral Artery Disease (PAD) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LSTA-12 development?
• What are the key designations that have been granted to LSTA-12 for PAD?
• What is the forecasted market scenario of LSTA-12 for PAD?
• What are the forecasted sales of LSTA-12 in Japan?
• What are the other emerging products available and how are these giving competition to LSTA-12 for PAD?
• Which are the late-stage emerging therapies under development for the treatment of PAD?

This product will be delivered within 2 business days.